Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma

NCT07864701 is registered in ClinicalTrials.gov with Chengdu Anticancer Bioscience, Ltd. as lead sponsor.

NCT NCT07864701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07864701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma
Lead sponsor
Chengdu Anticancer Bioscience, Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2030
Enrollment
150 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advance solid tumors, lymphoma, non-hodgkin